semaglutide bupropion Obesity drugs under review: Semaglutide, tirzepatide, naltrexone/bupropion all boost heart health Shed GLP-1 Review 2026 Explores

In December, however, the FDA confirmed that tirzepatide would no longer be in shortage, giving compounders up to 90 days to cease their production of the GLP-1 therapy

Among women diagnosed with type 2 diabetes before pregnancy, 5.3% of babies were born with severe birth defects, including 2.2% with heart defects, compared to the overall group where 3.8% had severe birth defects and 1.3% with heart defects

Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions

Pancreatic Mucinous Cystic Neoplasms Following GLP-1 Receptor Agonists Use: A Report of Two Cases with Literature Review

Demostr reduccin del riesgo de muerte por enfermedades crnicas metablicas y cardiovasculares

Gadanec et al., 2021)